ZVRA
NASDAQ
US
Zevra Therapeutics, Inc. - Common Stock
$9,40
▼ $-0,01
(-0,11%)
Vol. 587K
10
Punteggio di Qualità
ok
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$504.4M
P/E
14,3
ROE
42,7%
Margine
41,9%
D/E
46,04
Beta
1,00
52W
$6–$13
Consenso Wall Street
15 analisti · Apr 20265
Acquisto forte
9
Compra
1
Mantieni
0
Vendi
0
Vendita forte
93,3%
Rating Compra
Grafico dei Prezzi
Titoli simili
LXRX
Lexicon Pharmaceuticals Inc
$417.9M
ESPR
Esperion Therapeutics Inc
$884.5M
LBRX
LB Pharmaceuticals Inc
$563.2M
CRMD
CorMedix Inc
P/E 5,6
$916.3M
FULC
Fulcrum Therapeutics Inc
$746.1M
ACRS
Aclaris Therapeutics Inc
$326.1M
AQST
Aquestive Therapeutics Inc
$788.1M
AVIR
Atea Pharmaceuticals Inc
$278.9M
CTNM
Contineum Therapeutics Inc
$417.5M
Utili
Tasso di battuta: 75,0%
Prossimo report
Mag 11, 2026
Stima EPS: $0,09
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $0,09 | — | — |
| Dic 2025 | $0,05 | $0,21 | +$0,16 |
| Set 2025 | $-0,04 | $-0,01 | +$0,03 |
| Giu 2025 | $1,53 | $1,21 | $-0,32 |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 4.0% | -201.1% | 4.0% | 4.0% | 42.7% | 42.7% |
| P/E (TTM) | 182.20 | — | 153.50 | 236.73 | 13.43 | 14.28 |
| Net Margin | 288.7% | -226.6% | 4.3% | 4.3% | 41.9% | 41.9% |
| Gross Margin | 93.8% | 84.4% | 89.7% | 89.7% | 93.9% | 93.9% |
| D/E Ratio | 51.77 | 146.48 | 51.77 | 51.77 | 46.04 | 46.04 |
| Current Ratio | 7.85 | 3.02 | 7.85 | 7.85 | 8.62 | 8.62 |
Rapporti chiave
ROA (TTM)
16,1%
P/S (TTM)
5,98
P/B
11,2
EPS (TTM)
$0,59
CF/Share
$-1,15
Crescita ricavi 3A
-6,2%
52W High
$13,16
52W Low
$6,19
$6,19
Intervallo 52 settimane
$13,16
Як ZVRA виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка ZVRA vs аналоги Pharmaceuticals
P/E
14,3
▼
36%
sotto
peer
(22,4)
vs Peer
vs Settore
Sottovalutato
P/S
6,0
▲
21%
sopra
peer
(5,0)
vs Peer
vs Settore
Più costoso
P/B
11,2
▲
429%
sopra
peer
(2,1)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(2,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ZVRA vs аналоги Pharmaceuticals
ROE
42,7%
▲
179%
sopra
peer
(-54,3%)
vs Peer
vs Settore
Top livello
Net margin
41,9%
▲
188%
sopra
peer
(-47,4%)
vs Peer
vs Settore
Sotto media
Валова маржа
93,9%
▲
37%
sopra
peer
(68,3%)
vs Peer
vs Settore
Sotto media
ROA
16,1%
▲
143%
sopra
peer
(-37,4%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя ZVRA vs аналоги Pharmaceuticals
D/E ratio
46,0
▲
2890%
sopra
peer
(1,5)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
8,6
▲
157%
sopra
peer
(3,4)
vs Peer
vs Settore
Liquidità forte
Beta
1,0
▲
6%
sopra
peer
(0,9)
vs Peer
vs Settore
Meno volatile
Радар фундаменталів ZVRA
ZVRA
Mediana peer
Industria
ZVRA прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ZVRA vs аналоги: ключові метрики
Ultime notizie
Nessuna notizia correlata ancora